Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Kwiatkowski

Showing results (1-10 of 309) with videos related to

Pageof 31
Sort By:
Cancer Biology & Therapy|November 14, 2003
Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosisDavid J Kwiatkowski
Lymphatic Research and Biology|March 19, 2010
Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC)David J Kwiatkowski
Molecular Cancer Research : MCR|February 7, 2013
Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosisYanan Guo, David J Kwiatkowski
Molecular Cancer Therapeutics|October 29, 2014
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic targetYang Liu, David J Kwiatkowski
Ebiomedicine|July 3, 2015
mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?David J Kwiatkowski, Nikhil Wagle
JAMA Oncology|May 14, 2026
Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction-ReplyMehrdad Rakaee, David J Kwiatkowski
Human Pathology|July 17, 2009
Perivascular epithelioid cell neoplasms: pathology and pathogenesisAndrew L Folpe, David J Kwiatkowski
Lancet (London, England)|September 11, 2016
Seizures in tuberous sclerosis complex: hitting the targetE Steve Roach, David J Kwiatkowski
Human Molecular Genetics|October 26, 2005
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathwaysDavid J Kwiatkowski, Brendan D Manning
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Targeting molecular aberrations in urothelial carcinoma: are we almost there?Andrea B Apolo, David J Kwiatkowski
Pageof 31

Showing results (1-10 of 309) with videos related to

Sort By:
Pageof 31
Cancer Biology & Therapy|November 14, 2003
Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosisDavid J Kwiatkowski
Lymphatic Research and Biology|March 19, 2010
Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC)David J Kwiatkowski
Molecular Cancer Research : MCR|February 7, 2013
Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosisYanan Guo, David J Kwiatkowski
Molecular Cancer Therapeutics|October 29, 2014
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic targetYang Liu, David J Kwiatkowski
Ebiomedicine|July 3, 2015
mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?David J Kwiatkowski, Nikhil Wagle
JAMA Oncology|May 14, 2026
Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction-ReplyMehrdad Rakaee, David J Kwiatkowski
Human Pathology|July 17, 2009
Perivascular epithelioid cell neoplasms: pathology and pathogenesisAndrew L Folpe, David J Kwiatkowski
Lancet (London, England)|September 11, 2016
Seizures in tuberous sclerosis complex: hitting the targetE Steve Roach, David J Kwiatkowski
Human Molecular Genetics|October 26, 2005
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathwaysDavid J Kwiatkowski, Brendan D Manning
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Targeting molecular aberrations in urothelial carcinoma: are we almost there?Andrea B Apolo, David J Kwiatkowski
Pageof 31